Our mission
EASYGEN's (EASY Workflow Integration for GENe Therapy) mission is to help broaden access to advanced cell therapies through the development and evaluation of a scalable, automated, non-viral, point-of-care manufacturing platform that brings CAR-T production closer to the patient.
But technology alone is not enough. EASYGEN brings together manufacturing, quality control, digital integration, hospital workflows, health economics, regulatory considerations and patient perspectives to explore how decentralised CAR-T manufacturing could work in real healthcare environments.
Target a 50% reduction in treatment-related costs.
EASYGEN will evaluate whether decentralised and automated manufacturing can reduce manufacturing, logistics and other treatment-related costs.
Reduce manufacturing time to under 24 hours.
EASYGEN aims to shorten the manufacturing process from several weeks to less than 24 hours through an integrated, automated workflow.
Broaden access for more patients.
By reducing manufacturing and logistical constraints, EASYGEN aims to explore how more eligible patients could gain timely access to CAR-T therapy.
Embed decentralised manufacturing into routine hospital workflows.
EASYGEN is designed around the realities of healthcare delivery — exploring how manufacturing, quality control and digital processes can be integrated into qualified hospital environments while maintaining rigorous standards for quality and safety.
